EquiReason

EquiReason research coverage

Inhibrx Biosciences, Inc. INH

Healthcare · Biotechnology

5quarters analysed
12SEC filings read

Segments it reports

The business segments Inhibrx Biosciences, Inc. reports in its own SEC filings.

  • Reportable Segment

Product lines it reports

The product and service lines Inhibrx Biosciences, Inc. breaks its revenue into.

  • License Non Affiliate
  • License

What we read

The sources behind this company, and how many records of each we hold.

  • Financial statements11
  • Quarterly metric series12
  • SEC filings12
  • Insider transactions (Form 4)6
  • Institutional positions (13F)7
  • Earnings quality checks3
  • Estimate revisions10
  • Seasonal pattern6
  • Multi-period trajectory7
  • Inflection detection1
  • Fiscal calendar1
  • Index membership4

What we look for

Every company is run through the same checks. Both answers are reported — a signal we looked for and did not find is as much a fact as one we did.

  • Revenue series2
  • Earnings series5
  • Guidance changesnot found
  • Margin seriesnot found
  • Cash flow seriesnot found
  • Per-share seriesnot found
  • Operating cash flow seriesnot found

This page says how much of Inhibrx Biosciences, Inc. we have read. What any of it means — the direction, the dates, the evidence and what would overturn it — is inside the product.

Open INH in EquiReason

Coverage counts only. This page publishes no figures, no dates and no conclusions. Sources are SEC filings, earnings calls and public institutional disclosures. How the research is made · All companies

Inhibrx Biosciences, Inc. (INH) — research coverage | EquiReason